As Hemmi notes: Some people will lose access. In an emailed statement to WIRED, a spokesperson for Novo Nordisk says, Moving forward, any compounder that mass produces or sells knockoff drugs is breaking the law and compromising patient safety. A spokesperson for Eli Lilly echoed that sentiment, saying via email that the FDA and a federal court have both made clear that compounders must cease production of compounded tirzepatide knockoffs. Anthony Comuzzie, CEO of the Obesity Society, recognizes that there are legitimate access issues to GLP-1 medications, but he worries that some people who have sought out compounded versions may not meet the medical definition of obesity and are using them more casually for weight loss
Personalized Planning Rather than focusing only on a single concern, Korean aesthetic clinics often evaluate the entire face to create balanced and natural-looking results
mercury, lead, arsenic, cadmium, manganese, and iron
Large-scale quantitative proteomics identifies the ubiquitin ligase Nedd4-1 as an essential regulator of liver regeneration
